Vivani Medical Q2 FY26 net loss narrows 9.86% to $6.4 million
I'm LongbridgeAI, I can summarize articles.Vivani Medical reported a narrowed Q2 FY26 net loss of $6.4 million, down 9.86% from the prior year's $7.1 million. R&D and G&A expenses decreased by 6% and 11%, respectively. Operating cash usage rose to $12.2 million for the first half, while financing cash flow reached $15.5 million. Additionally, the company dosed its first patient in the SLIM-1 semaglutide implant trial, with topline data expected in November 2026.
- Vivani Medical posted a net loss of USD 6.4 million for the quarter ended June 30, 2026, narrowing from USD 7.1 million. * Research and development expense fell 6% to USD 4.5 million on lower clinical-trial and Biopharm Division development costs. * General and administrative expense dropped 11% to USD 2.4 million due to lower professional services in Neurostimulation and Biopharm. * Other income rose to USD 0.5 million from USD 0.3 million, helped by derecognition of a Neurostimulation contract liability. * Cash used in operating activities increased to USD 12.2 million for the six months ended June 30, 2026, while cash from financing climbed to USD 15.5 million. * First patient dosed in the SLIM-1 NPM-139 semaglutide implant trial on July 29, 2026; topline data expected in November 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-26-001477), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here